The 17‐gene stemness score associates with relapse risk and long‐term outcomes following allogeneic haematopoietic cell transplantation in acute myeloid leukaemia

A 17‐gene stemness (LSC17) score determines risk in acute myeloid leukaemia patients treated with standard chemotherapy regimens. The present study further analysed the impact of the LSC17 score at diagnosis on outcomes following allogeneic haematopoietic cell transplantation (HCT). Out of 452 patie...

Full description

Saved in:

Bibliographic Details
Published in	EJHaem Vol. 3; no. 3; pp. 873 - 884
Main Authors	Kim, Dennis D. H., Novitzky Basso, Igor, Kim, Taehyung Simon, Yi, Seong Yoon, Kim, Kyoung Ha, Murphy, Tracy, Chan, Steven, Minden, Mark, Pasic, Ivan, Lam, Wilson, Law, Arjun, Michelis, Fotios V., Gerbitz, Armin, Viswabandya, Auro, Lipton, Jeffrey, Kumar, Rajat, Ng, Stanley W. K., Stockley, Tracy, Zhang, Tong, King, Ian, Mattsson, Jonas, Wang, Jean C. Y.
Format	Journal Article
Language	English
Published	United States John Wiley & Sons, Inc 01.08.2022 John Wiley and Sons Inc Wiley
Subjects	Acute leukaemia Acute myeloid leukemia Age AML Bone marrow Cell Therapy/Stem Cell Transplantation Chemotherapy Gene expression Leukemia LSC 17 score Management decisions Mortality Patients Remission (Medicine) Statistical analysis Stem cell transplantation Stem cells Transplantation Transplants & implants Variables AML Stem cell transplantation LSC 17 score Gene expression Acute leukaemia
Online Access	Get full text
ISSN	2688-6146 2688-6146
DOI	10.1002/jha2.466

Cover

Abstract	A 17‐gene stemness (LSC17) score determines risk in acute myeloid leukaemia patients treated with standard chemotherapy regimens. The present study further analysed the impact of the LSC17 score at diagnosis on outcomes following allogeneic haematopoietic cell transplantation (HCT). Out of 452 patients with available LSC17 score, 123 patients received allogeneic HCT. Transplant outcomes, including overall (OS), leukaemia‐free survival (LFS), relapse incidence (RI) and non‐relapse mortality (NRM), were compared according to the LSC17 scored group. The patients with a low LSC17 score had higher OS (56.2%) and LFS (54.4%) at 2 years compared to patients with high LSC17 score (47.2%, p = 0.0237 for OS and 46.0%, p = 0.0181 for LFS). The low LSC17 score group also had a lower relapse rate at 2 years (12.7%) compared to 25.3% in the high LSC17 score group (p = 0.017), but no difference in NRM (p = 0.674). Worse outcomes in the high LSC17 score group for OS, LFS and relapse were consistently observed across all stratified sub‐groups. The use of more intensive conditioning did not improve outcomes for either group. In contrast, chronic graft‐versus‐host‐disease was associated with more favourable outcomes in both groups. The 17‐gene stemness score is highly prognostic for survival and relapse risk following allogeneic HCT.
AbstractList	A 17‐gene stemness (LSC17) score determines risk in acute myeloid leukaemia patients treated with standard chemotherapy regimens. The present study further analysed the impact of the LSC17 score at diagnosis on outcomes following allogeneic haematopoietic cell transplantation (HCT). Out of 452 patients with available LSC17 score, 123 patients received allogeneic HCT. Transplant outcomes, including overall (OS), leukaemia‐free survival (LFS), relapse incidence (RI) and non‐relapse mortality (NRM), were compared according to the LSC17 scored group. The patients with a low LSC17 score had higher OS (56.2%) and LFS (54.4%) at 2 years compared to patients with high LSC17 score (47.2%, p = 0.0237 for OS and 46.0%, p = 0.0181 for LFS). The low LSC17 score group also had a lower relapse rate at 2 years (12.7%) compared to 25.3% in the high LSC17 score group (p = 0.017), but no difference in NRM (p = 0.674). Worse outcomes in the high LSC17 score group for OS, LFS and relapse were consistently observed across all stratified sub‐groups. The use of more intensive conditioning did not improve outcomes for either group. In contrast, chronic graft‐versus‐host‐disease was associated with more favourable outcomes in both groups. The 17‐gene stemness score is highly prognostic for survival and relapse risk following allogeneic HCT. A 17-gene stemness (LSC17) score determines risk in acute myeloid leukaemia patients treated with standard chemotherapy regimens. The present study further analysed the impact of the LSC17 score at diagnosis on outcomes following allogeneic haematopoietic cell transplantation (HCT). Out of 452 patients with available LSC17 score, 123 patients received allogeneic HCT. Transplant outcomes, including overall (OS), leukaemia-free survival (LFS), relapse incidence (RI) and non-relapse mortality (NRM), were compared according to the LSC17 scored group. The patients with a low LSC17 score had higher OS (56.2%) and LFS (54.4%) at 2 years compared to patients with high LSC17 score (47.2%, = 0.0237 for OS and 46.0%, = 0.0181 for LFS). The low LSC17 score group also had a lower relapse rate at 2 years (12.7%) compared to 25.3% in the high LSC17 score group ( = 0.017), but no difference in NRM ( = 0.674). Worse outcomes in the high LSC17 score group for OS, LFS and relapse were consistently observed across all stratified sub-groups. The use of more intensive conditioning did not improve outcomes for either group. In contrast, chronic graft-versus-host-disease was associated with more favourable outcomes in both groups. The 17-gene stemness score is highly prognostic for survival and relapse risk following allogeneic HCT. A 17-gene stemness (LSC17) score determines risk in acute myeloid leukaemia patients treated with standard chemotherapy regimens. The present study further analysed the impact of the LSC17 score at diagnosis on outcomes following allogeneic haematopoietic cell transplantation (HCT). Out of 452 patients with available LSC17 score, 123 patients received allogeneic HCT. Transplant outcomes, including overall (OS), leukaemia-free survival (LFS), relapse incidence (RI) and non-relapse mortality (NRM), were compared according to the LSC17 scored group. The patients with a low LSC17 score had higher OS (56.2%) and LFS (54.4%) at 2 years compared to patients with high LSC17 score (47.2%, p = 0.0237 for OS and 46.0%, p = 0.0181 for LFS). The low LSC17 score group also had a lower relapse rate at 2 years (12.7%) compared to 25.3% in the high LSC17 score group (p = 0.017), but no difference in NRM (p = 0.674). Worse outcomes in the high LSC17 score group for OS, LFS and relapse were consistently observed across all stratified sub-groups. The use of more intensive conditioning did not improve outcomes for either group. In contrast, chronic graft-versus-host-disease was associated with more favourable outcomes in both groups. The 17-gene stemness score is highly prognostic for survival and relapse risk following allogeneic HCT.A 17-gene stemness (LSC17) score determines risk in acute myeloid leukaemia patients treated with standard chemotherapy regimens. The present study further analysed the impact of the LSC17 score at diagnosis on outcomes following allogeneic haematopoietic cell transplantation (HCT). Out of 452 patients with available LSC17 score, 123 patients received allogeneic HCT. Transplant outcomes, including overall (OS), leukaemia-free survival (LFS), relapse incidence (RI) and non-relapse mortality (NRM), were compared according to the LSC17 scored group. The patients with a low LSC17 score had higher OS (56.2%) and LFS (54.4%) at 2 years compared to patients with high LSC17 score (47.2%, p = 0.0237 for OS and 46.0%, p = 0.0181 for LFS). The low LSC17 score group also had a lower relapse rate at 2 years (12.7%) compared to 25.3% in the high LSC17 score group (p = 0.017), but no difference in NRM (p = 0.674). Worse outcomes in the high LSC17 score group for OS, LFS and relapse were consistently observed across all stratified sub-groups. The use of more intensive conditioning did not improve outcomes for either group. In contrast, chronic graft-versus-host-disease was associated with more favourable outcomes in both groups. The 17-gene stemness score is highly prognostic for survival and relapse risk following allogeneic HCT. A 17‐gene stemness (LSC17) score determines risk in acute myeloid leukaemia patients treated with standard chemotherapy regimens. The present study further analysed the impact of the LSC17 score at diagnosis on outcomes following allogeneic haematopoietic cell transplantation (HCT). Out of 452 patients with available LSC17 score, 123 patients received allogeneic HCT. Transplant outcomes, including overall (OS), leukaemia‐free survival (LFS), relapse incidence (RI) and non‐relapse mortality (NRM), were compared according to the LSC17 scored group. The patients with a low LSC17 score had higher OS (56.2%) and LFS (54.4%) at 2 years compared to patients with high LSC17 score (47.2%, p = 0.0237 for OS and 46.0%, p = 0.0181 for LFS). The low LSC17 score group also had a lower relapse rate at 2 years (12.7%) compared to 25.3% in the high LSC17 score group ( p = 0.017), but no difference in NRM ( p = 0.674). Worse outcomes in the high LSC17 score group for OS, LFS and relapse were consistently observed across all stratified sub‐groups. The use of more intensive conditioning did not improve outcomes for either group. In contrast, chronic graft‐versus‐host‐disease was associated with more favourable outcomes in both groups. The 17‐gene stemness score is highly prognostic for survival and relapse risk following allogeneic HCT. Abstract A 17‐gene stemness (LSC17) score determines risk in acute myeloid leukaemia patients treated with standard chemotherapy regimens. The present study further analysed the impact of the LSC17 score at diagnosis on outcomes following allogeneic haematopoietic cell transplantation (HCT). Out of 452 patients with available LSC17 score, 123 patients received allogeneic HCT. Transplant outcomes, including overall (OS), leukaemia‐free survival (LFS), relapse incidence (RI) and non‐relapse mortality (NRM), were compared according to the LSC17 scored group. The patients with a low LSC17 score had higher OS (56.2%) and LFS (54.4%) at 2 years compared to patients with high LSC17 score (47.2%, p = 0.0237 for OS and 46.0%, p = 0.0181 for LFS). The low LSC17 score group also had a lower relapse rate at 2 years (12.7%) compared to 25.3% in the high LSC17 score group (p = 0.017), but no difference in NRM (p = 0.674). Worse outcomes in the high LSC17 score group for OS, LFS and relapse were consistently observed across all stratified sub‐groups. The use of more intensive conditioning did not improve outcomes for either group. In contrast, chronic graft‐versus‐host‐disease was associated with more favourable outcomes in both groups. The 17‐gene stemness score is highly prognostic for survival and relapse risk following allogeneic HCT. A 17-gene stemness (LSC17) score determines risk in acute myeloid leukaemia patients treated with standard chemotherapy regimens. The present study further analysed the impact of the LSC17 score at diagnosis on outcomes following allogeneic haematopoietic cell transplantation (HCT). Out of 452 patients with available LSC17 score, 123 patients received allogeneic HCT. Transplant outcomes, including overall (OS), leukaemia-free survival (LFS), relapse incidence (RI) and non-relapse mortality (NRM), were compared according to the LSC17 scored group. The patients with a low LSC17 score had higher OS (56.2%) and LFS (54.4%) at 2 years compared to patients with high LSC17 score (47.2%, p = 0.0237 for OS and 46.0%, p = 0.0181 for LFS). The low LSC17 score group also had a lower relapse rate at 2 years (12.7%) compared to 25.3% in the high LSC17 score group (p = 0.017), but no difference in NRM (p = 0.674). Worse outcomes in the high LSC17 score group for OS, LFS and relapse were consistently observed across all stratified sub-groups. The use of more intensive conditioning did not improve outcomes for either group. In contrast, chronic graft-versus-host-disease was associated with more favourable outcomes in both groups. The 17-gene stemness score is highly prognostic for survival and relapse risk following allogeneic HCT.
Author	Kim, Taehyung Simon Law, Arjun Ng, Stanley W. K. Kim, Kyoung Ha Pasic, Ivan Lam, Wilson Yi, Seong Yoon Viswabandya, Auro Gerbitz, Armin Michelis, Fotios V. Kumar, Rajat Kim, Dennis D. H. Chan, Steven Stockley, Tracy Mattsson, Jonas Lipton, Jeffrey Minden, Mark Zhang, Tong Wang, Jean C. Y. Novitzky Basso, Igor Murphy, Tracy King, Ian
AuthorAffiliation	3 Department of Computer Science University of Toronto Toronto Canada 1 Department of Medical Oncology and Hematology Princess Margaret Cancer Centre University of Toronto Toronto Canada 7 Cancer Genome Project Wellcome Sanger Institute Hinxton UK 11 Gloria and Seymour Epstein Chair in Cell Therapy and Transplantation Princess Margaret Cancer Centre Toronto Canada 4 The Donnelly Centre for Cellular and Biomolecular Research University of Toronto Toronto Canada 12 Department of Medical Oncology and Hematology Princess Margaret Cancer Centre University of Toronto Toronto Canada 6 Department of Internal Medicine College of Medicine Seoul Hospital Soonchunhyang University Seoul Korea 8 The Advanced Molecular Diagnostics Lab Princess Margaret Cancer Centre Toronto Canada 10 Department of Laboratory Medicine and Pathobiology University of Toronto Toronto Canada 5 Department of Internal Medicine Inje University Ilsan Paik Hospital Goyang Korea 9 Clinical Laboratory Genetics Laboratory Medicine Program
AuthorAffiliation_xml	– name: 7 Cancer Genome Project Wellcome Sanger Institute Hinxton UK – name: 10 Department of Laboratory Medicine and Pathobiology University of Toronto Toronto Canada – name: 8 The Advanced Molecular Diagnostics Lab Princess Margaret Cancer Centre Toronto Canada – name: 2 Faculty of Medicine University of Toronto Toronto Canada – name: 3 Department of Computer Science University of Toronto Toronto Canada – name: 4 The Donnelly Centre for Cellular and Biomolecular Research University of Toronto Toronto Canada – name: 9 Clinical Laboratory Genetics Laboratory Medicine Program University Health Network Toronto Canada – name: 11 Gloria and Seymour Epstein Chair in Cell Therapy and Transplantation Princess Margaret Cancer Centre Toronto Canada – name: 5 Department of Internal Medicine Inje University Ilsan Paik Hospital Goyang Korea – name: 1 Department of Medical Oncology and Hematology Princess Margaret Cancer Centre University of Toronto Toronto Canada – name: 6 Department of Internal Medicine College of Medicine Seoul Hospital Soonchunhyang University Seoul Korea – name: 12 Department of Medical Oncology and Hematology Princess Margaret Cancer Centre University of Toronto Toronto Canada
Author_xml	– sequence: 1 givenname: Dennis D. H. surname: Kim fullname: Kim, Dennis D. H. email: dr.dennis.kim@uhn.ca organization: University of Toronto – sequence: 2 givenname: Igor surname: Novitzky Basso fullname: Novitzky Basso, Igor organization: University of Toronto – sequence: 3 givenname: Taehyung Simon surname: Kim fullname: Kim, Taehyung Simon organization: University of Toronto – sequence: 4 givenname: Seong Yoon surname: Yi fullname: Yi, Seong Yoon organization: Inje University Ilsan Paik Hospital – sequence: 5 givenname: Kyoung Ha surname: Kim fullname: Kim, Kyoung Ha organization: Soonchunhyang University – sequence: 6 givenname: Tracy surname: Murphy fullname: Murphy, Tracy organization: University of Toronto – sequence: 7 givenname: Steven surname: Chan fullname: Chan, Steven organization: University of Toronto – sequence: 8 givenname: Mark surname: Minden fullname: Minden, Mark organization: University of Toronto – sequence: 9 givenname: Ivan surname: Pasic fullname: Pasic, Ivan organization: University of Toronto – sequence: 10 givenname: Wilson surname: Lam fullname: Lam, Wilson organization: University of Toronto – sequence: 11 givenname: Arjun orcidid: 0000-0002-9251-3609 surname: Law fullname: Law, Arjun organization: University of Toronto – sequence: 12 givenname: Fotios V. orcidid: 0000-0003-2956-0848 surname: Michelis fullname: Michelis, Fotios V. organization: University of Toronto – sequence: 13 givenname: Armin surname: Gerbitz fullname: Gerbitz, Armin organization: University of Toronto – sequence: 14 givenname: Auro surname: Viswabandya fullname: Viswabandya, Auro organization: University of Toronto – sequence: 15 givenname: Jeffrey orcidid: 0000-0001-7391-7168 surname: Lipton fullname: Lipton, Jeffrey organization: University of Toronto – sequence: 16 givenname: Rajat surname: Kumar fullname: Kumar, Rajat organization: University of Toronto – sequence: 17 givenname: Stanley W. K. surname: Ng fullname: Ng, Stanley W. K. organization: Wellcome Sanger Institute – sequence: 18 givenname: Tracy surname: Stockley fullname: Stockley, Tracy organization: University of Toronto – sequence: 19 givenname: Tong surname: Zhang fullname: Zhang, Tong organization: Princess Margaret Cancer Centre – sequence: 20 givenname: Ian surname: King fullname: King, Ian organization: Princess Margaret Cancer Centre – sequence: 21 givenname: Jonas surname: Mattsson fullname: Mattsson, Jonas organization: Princess Margaret Cancer Centre – sequence: 22 givenname: Jean C. Y. surname: Wang fullname: Wang, Jean C. Y. organization: University of Toronto
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/36051057$$D View this record in MEDLINE/PubMed http://kipublications.ki.se/Default.aspx?queryparsed=id:236051057$$DView record from Swedish Publication Index
BookMark	eNp1ksFuEzEQhleoiJZSiSdAlrhwSbB3vfbuBamqgBZV4lLO1sQ7mzj12sH2NsqNR-ApeDCeBIekpUFw8nj8za9_xvO8OHLeYVG8ZHTKKC3fLhdQTrkQT4qTUjTNRDAujh7Fx8VZjEua0YrVomLPiuNK0JrRWp4UP24WSJj8-e37HB2SmHBwGCOJ2gckEKPXBhJGsjZpQQJaWEUkwcRbAq4j1rt5rk0YBuLHpP2Q0d5b69fGzQnkYKtrNFkADpD8yhtM-arRWpICuLiy4BIk4x0xjoAeE5Jhg9abLI_jba4z8KJ42oONeLY_T4svH97fXFxOrj9_vLo4v55oLksxkTWteuBai05jJTva9DWlLW11zVmH0LdCywZpiaCpFpzytqmkkDMUdNb0UJ0WVzvdzsNSrYIZIGyUB6N-J3yYKwjZv0VViRaaUvQzzjWndd2gROyobFsmOt6wrDXZacU1rsbZgdo-dZsjVLxmrCoz_27H55cBcwMuz8celB2-OLNQc3-nWl6WlIks8GYvEPzXEWNSg4nbQYNDP0ZVStrKitdNk9HXf6FLPwaXR7ulZF3J3FKmXj129GDlfn0yMN0BOvgYA_ZKm91fZoPGKkbVdkXVdkVVXtE_Fh8K7jX_ge7HtzYWN__l1KfL83LL_wK4oPpM
CitedBy_id	crossref_primary_10_3390_cancers15215289
Cites_doi	10.1056/NEJM199812033392301 10.1016/j.bbmt.2007.07.003 10.1002/sim.6765 10.1158/1078-0432.CCR-14-0586 10.1038/s41375-019-0604-8 10.1007/s00277-018-3391-9 10.1097/MOH.0000000000000572 10.2307/2533069 10.1038/bmt.2012.244 10.1182/blood-2009-07-235358 10.1038/bmt.2015.59 10.1038/nature20598 10.1056/NEJMoa0903840 10.1182/blood-2016-08-733196 10.1016/j.bbmt.2016.08.030 10.1182/asheducation-2015.1.225 10.1016/j.bbmt.2018.07.008 10.1038/s41375-018-0227-5 10.1200/JCO.2006.06.2679 10.1016/j.bbmt.2014.12.001 10.3324/haematol.2019.225003 10.1001/jama.2010.1862 10.1158/1078-0432.CCR-14-2930 10.1038/bmt.2015.165 10.3324/haematol.2011.051714 10.1182/bloodadvances.2019001185 10.1002/ajh.24113 10.1182/blood-2009-11-254441
ContentType	Journal Article
Copyright	2022 The Authors. published by British Society for Haematology and John Wiley & Sons Ltd. 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml	– notice: 2022 The Authors. published by British Society for Haematology and John Wiley & Sons Ltd. – notice: 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. – notice: 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID	24P AAYXX CITATION NPM 8FE 8FH ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO GNUQQ HCIFZ LK8 M7P PHGZM PHGZT PIMPY PKEHL PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM ADTPV AOWAS D8T ZZAVC DOA
DOI	10.1002/jha2.466
DatabaseName	Wiley Online Library Open Access CrossRef PubMed ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Central ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One ProQuest Central ProQuest Central Student SciTech Premium Collection (via ProQuest) ProQuest Biological Science Collection Biological Science Database (Proquest) ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) SwePub SwePub Articles SWEPUB Freely available online SwePub Articles full text DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef PubMed Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Biological Science Collection ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection Biological Science Database ProQuest SciTech Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Academic UKI Edition Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) MEDLINE - Academic
DatabaseTitleList	PubMed MEDLINE - Academic CrossRef Publicly Available Content Database
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
DocumentTitleAlternate	KIM et al
EISSN	2688-6146
EndPage	884
ExternalDocumentID	oai_doaj_org_article_369a826fb44c40558e7eed079916d481 oai_swepub_ki_se_451132 PMC9422016 36051057 10_1002_jha2_466 JHA2466
Genre	article Journal Article
GrantInformation_xml	– fundername: Ontario Institute for Cancer Research – fundername: Princess Margaret Cancer Foundation – fundername: Leukemia & Lymphoma Society of Canada – fundername: ;
GroupedDBID	0R~ 1OC 24P 53G AAHHS ACCFJ ACCMX ACXQS ADKYN ADPDF ADZMN AEEZP AEQDE AFKRA AIWBW AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN AVUZU BBNVY BENPR BHPHI CCPQU EBS GROUPED_DOAJ HCIFZ IAO IHR INH ITC M7P M~E OVD OVEED PGMZT PIMPY RPM TEORI WIN AAFWJ AAYXX AFPKN CITATION PHGZM PHGZT NPM 8FE 8FH AAMMB ABUWG AEFGJ AGXDD AIDQK AIDYY AZQEC DWQXO GNUQQ LK8 PKEHL PQEST PQGLB PQQKQ PQUKI PRINS 7X8 PUEGO 5PM ADTPV AOWAS D8T ZZAVC
ID	FETCH-LOGICAL-c4726-7503fa4cc6dce37d08f500909c541deaf96c78e02eac0c6404983767be60b8fa3
IEDL.DBID	DOA
ISSN	2688-6146
IngestDate	Wed Aug 27 01:18:22 EDT 2025 Wed Sep 24 03:41:58 EDT 2025 Thu Aug 21 18:21:22 EDT 2025 Thu Sep 04 18:20:49 EDT 2025 Wed Aug 13 04:38:48 EDT 2025 Wed Feb 19 02:18:42 EST 2025 Tue Jul 01 04:19:26 EDT 2025 Thu Apr 24 23:03:12 EDT 2025 Wed Jan 22 16:22:42 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	3
Keywords	AML Stem cell transplantation LSC 17 score Gene expression Acute leukaemia
Language	English
License	Attribution 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c4726-7503fa4cc6dce37d08f500909c541deaf96c78e02eac0c6404983767be60b8fa3
Notes	Dennis D. H. Kim and Igor Novitzky Basso contributed equally to this work as co‐first author. Jonas Mattsson and Jean C. Y. Wang contributed equally to this work as co‐senior author. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ORCID	0000-0003-2956-0848 0000-0001-7391-7168 0000-0002-9251-3609
OpenAccessLink	https://doaj.org/article/369a826fb44c40558e7eed079916d481
PMID	36051057
PQID	2707537405
PQPubID	5066168
PageCount	12
ParticipantIDs	doaj_primary_oai_doaj_org_article_369a826fb44c40558e7eed079916d481 swepub_primary_oai_swepub_ki_se_451132 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9422016 proquest_miscellaneous_2709734588 proquest_journals_2707537405 pubmed_primary_36051057 crossref_citationtrail_10_1002_jha2_466 crossref_primary_10_1002_jha2_466 wiley_primary_10_1002_jha2_466_JHA2466
ProviderPackageCode	CITATION AAYXX
PublicationCentury	2000
PublicationDate	August 2022
PublicationDateYYYYMMDD	2022-08-01
PublicationDate_xml	– month: 08 year: 2022 text: August 2022
PublicationDecade	2020
PublicationPlace	United States
PublicationPlace_xml	– name: United States – name: Hoboken
PublicationTitle	EJHaem
PublicationTitleAlternate	EJHaem
PublicationYear	2022
Publisher	John Wiley & Sons, Inc John Wiley and Sons Inc Wiley
Publisher_xml	– name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc – name: Wiley
References	2013; 48 1995; 15 2019; 33 2015; 50 2010; 304 1998; 339 2020; 105 2016; 540 1996; 52 2017; 130 2020; 34 2007; 13 2016; 35 2012; 97 2018; 24 2020; 4 2006; 24 2010; 116 2010; 115 2015; 21 2015; 2015 2020; 27 1998; 92 2009; 361 2014 2015; 90 2018; 97 2017; 129 2016; 22 e_1_2_8_28_1 e_1_2_8_29_1 e_1_2_8_24_1 e_1_2_8_25_1 e_1_2_8_26_1 e_1_2_8_27_1 Sloan CE (e_1_2_8_10_1) 2014 e_1_2_8_3_1 e_1_2_8_2_1 Smith JL (e_1_2_8_31_1) 2017; 130 e_1_2_8_5_1 e_1_2_8_4_1 e_1_2_8_6_1 e_1_2_8_9_1 e_1_2_8_8_1 e_1_2_8_20_1 Grimwade D (e_1_2_8_7_1) 1998; 92 e_1_2_8_21_1 e_1_2_8_22_1 e_1_2_8_23_1 e_1_2_8_17_1 e_1_2_8_18_1 e_1_2_8_13_1 e_1_2_8_14_1 e_1_2_8_15_1 e_1_2_8_16_1 Przepiorka D (e_1_2_8_19_1) 1995; 15 e_1_2_8_32_1 e_1_2_8_11_1 e_1_2_8_34_1 e_1_2_8_12_1 e_1_2_8_33_1 e_1_2_8_30_1
References_xml	– volume: 22 start-page: 2270 issue: 12 year: 2016 end-page: 5 article-title: Myeloablative versus reduced‐intensity conditioning in patients with myeloid malignancies: a propensity score‐matched analysis publication-title: Biol Blood Marrow Transplant – volume: 13 start-page: 1233 issue: 10 year: 2007 end-page: 43 article-title: Similar outcomes of cryopreserved allogeneic peripheral stem cell transplants (PBSCT) compared to fresh allografts publication-title: Biol Blood Marrow Transplant – volume: 24 start-page: 2259 issue: 11 year: 2018 end-page: 64 article-title: Reduced‐intensity conditioning and dual T lymphocyte suppression with antithymocyte globulin and post‐transplant cyclophosphamide as graft‐versus‐host disease prophylaxis in haploidentical hematopoietic stem cell transplants for hematological malignancies publication-title: Biol Blood Marrow Transplant – volume: 34 start-page: 735 issue: 3 year: 2020 end-page: 45 article-title: A six‐gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia publication-title: Leukemia – volume: 24 start-page: 5742 issue: 36 year: 2006 end-page: 9 article-title: Superiority of allogeneic hematopoietic stem‐cell transplantation compared with chemotherapy alone in high‐risk childhood T‐cell acute lymphoblastic leukemia: results from ALL‐BFM 90 and 95 publication-title: J Clin Oncol – volume: 92 start-page: 2322 issue: 7 year: 1998 end-page: 33 article-title: The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial publication-title: Blood, J Am Soc Hematol – volume: 339 start-page: 1649 issue: 23 year: 1998 end-page: 56 article-title: Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission publication-title: New Engl J Med – volume: 2015 start-page: 225 year: 2015 end-page: 30 article-title: Graft‐versus‐host disease versus graft‐versus‐leukemia publication-title: Hematology Am Soc Hematol Educ Program – volume: 33 start-page: 348 issue: 2 year: 2019 end-page: 57 article-title: The stem cell‐associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia publication-title: Leukemia – volume: 115 start-page: 453 issue: 3 year: 2010 end-page: 74 article-title: Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet publication-title: Blood – volume: 15 start-page: 825 issue: 6 year: 1995 end-page: 8 article-title: 1994 Consensus conference on acute GVHD grading publication-title: Bone Marrow Transplant – volume: 129 start-page: 424 issue: 4 year: 2017 end-page: 47 article-title: Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel publication-title: Blood – volume: 540 start-page: 433 issue: 7633 year: 2016 end-page: 7 article-title: A 17‐gene stemness score for rapid determination of risk in acute leukaemia publication-title: Nature – year: 2014 – volume: 4 start-page: 644 issue: 4 year: 2020 end-page: 54 article-title: A 4‐gene leukemic stem cell score can independently predict the prognosis of myelodysplastic syndrome patients publication-title: Blood Adv – volume: 21 start-page: 2020 issue: 9 year: 2015 end-page: 8 article-title: Impact of chronic graft‐versus‐host disease on late relapse and survival on 7489 patients after myeloablative allogeneic hematopoietic cell transplantation for leukemia publication-title: Clin Cancer Res – volume: 97 start-page: 1975 issue: 10 year: 2018 end-page: 85 article-title: Fludarabine and busulfan plus low‐dose TBI as reduced intensity conditioning in older patients undergoing allogeneic hematopoietic cell transplant for myeloid malignancies publication-title: Ann Hematol – volume: 52 start-page: 1079 issue: 3 year: 1996 end-page: 86 article-title: Analysis of time to death after transplantation when transplants are only given to patients in remission publication-title: Biometrics – volume: 97 start-page: 21 issue: 1 year: 2012 end-page: 9 article-title: The role of matched sibling donor allogeneic stem cell transplantation in pediatric high‐risk acute myeloid leukemia: results from the AML‐BFM 98 study publication-title: Haematologica – volume: 105 start-page: 721 issue: 3 year: 2020 end-page: 9 article-title: Mutations associated with a 17‐gene leukemia stem cell score and the score's prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemia publication-title: Haematologica – volume: 116 start-page: 354 issue: 3 year: 2010 end-page: 65 article-title: Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials publication-title: Blood – volume: 48 start-page: 452 issue: 3 year: 2013 end-page: 8 article-title: Investigation of the freely available easy‐to‐use software ‘EZR' for medical statistics publication-title: Bone Marrow Transplant – volume: 361 start-page: 1058 issue: 11 year: 2009 end-page: 66 article-title: Recurring mutations found by sequencing an acute myeloid leukemia genome publication-title: New Engl. J. Med. – volume: 35 start-page: 1032 issue: 7 year: 2016 end-page: 48 article-title: Survival probabilities with time‐dependent treatment indicator: quantities and non‐parametric estimators publication-title: Stat Med – volume: 130 start-page: 24 issue: 1 year: 2017 article-title: The LSC17 leukemic stem cell signature predicts outcome in pediatric acute myeloid leukemia publication-title: Blood – volume: 304 start-page: 2706 issue: 24 year: 2010 end-page: 15 article-title: Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia publication-title: JAMA – volume: 50 start-page: 907 issue: 7 year: 2015 end-page: 13 article-title: Comparable outcomes post allogeneic hematopoietic cell transplant for patients with de novo or secondary acute myeloid leukemia in first remission publication-title: Bone Marrow Transplant – volume: 27 start-page: 115 issue: 2 year: 2020 end-page: 21 article-title: Recent advances in allogeneic hematopoietic cell transplantation for acute myeloid leukemia publication-title: Curr Opin Hematol – volume: 21 start-page: 1981 issue: 9 year: 2015 end-page: 3 article-title: The Yin and Yang of alloreactivity: chronic graft‐versus‐host disease and leukemia relapse publication-title: Clin Cancer Res – volume: 90 start-page: 904 issue: 10 year: 2015 end-page: 9 article-title: Assessing the efficacy of allogeneic hematopoietic stem cells transplantation (allo‐HSCT) by analyzing survival end points in defined groups of acute myeloid leukemia patients: a retrospective, multicenter Polish Adult Leukemia Group study publication-title: Am J Hematol – volume: 21 start-page: 389 issue: 3 year: 2015 end-page: 401 article-title: National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft‐versus‐host disease: I. The 2014 Diagnosis and Staging Working Group report publication-title: Biol Blood Marrow Transplant – volume: 50 start-page: 1405 issue: 11 year: 2015 end-page: 10 article-title: Patient age, remission status and HCT‐CI in a combined score are prognostic for patients with AML undergoing allogeneic hematopoietic cell transplantation in CR1 and CR2 publication-title: Bone Marrow Transplant – ident: e_1_2_8_2_1 doi: 10.1056/NEJM199812033392301 – ident: e_1_2_8_17_1 doi: 10.1016/j.bbmt.2007.07.003 – ident: e_1_2_8_20_1 doi: 10.1002/sim.6765 – ident: e_1_2_8_26_1 doi: 10.1158/1078-0432.CCR-14-0586 – ident: e_1_2_8_33_1 doi: 10.1038/s41375-019-0604-8 – ident: e_1_2_8_14_1 doi: 10.1007/s00277-018-3391-9 – ident: e_1_2_8_3_1 doi: 10.1097/MOH.0000000000000572 – ident: e_1_2_8_24_1 doi: 10.2307/2533069 – ident: e_1_2_8_25_1 doi: 10.1038/bmt.2012.244 – ident: e_1_2_8_11_1 doi: 10.1182/blood-2009-07-235358 – ident: e_1_2_8_16_1 doi: 10.1038/bmt.2015.59 – ident: e_1_2_8_12_1 doi: 10.1038/nature20598 – volume: 92 start-page: 2322 issue: 7 year: 1998 ident: e_1_2_8_7_1 article-title: The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial publication-title: Blood, J Am Soc Hematol – ident: e_1_2_8_9_1 doi: 10.1056/NEJMoa0903840 – ident: e_1_2_8_5_1 doi: 10.1182/blood-2016-08-733196 – ident: e_1_2_8_15_1 doi: 10.1016/j.bbmt.2016.08.030 – ident: e_1_2_8_28_1 doi: 10.1182/asheducation-2015.1.225 – ident: e_1_2_8_13_1 doi: 10.1016/j.bbmt.2018.07.008 – ident: e_1_2_8_30_1 doi: 10.1038/s41375-018-0227-5 – ident: e_1_2_8_23_1 doi: 10.1200/JCO.2006.06.2679 – volume-title: Predicting prognosis in patients with acute myeloid leukemia: The role of next‐generation sequencing and mutational profiling year: 2014 ident: e_1_2_8_10_1 – ident: e_1_2_8_18_1 doi: 10.1016/j.bbmt.2014.12.001 – ident: e_1_2_8_29_1 doi: 10.3324/haematol.2019.225003 – ident: e_1_2_8_34_1 doi: 10.1001/jama.2010.1862 – ident: e_1_2_8_27_1 doi: 10.1158/1078-0432.CCR-14-2930 – volume: 130 start-page: 24 issue: 1 year: 2017 ident: e_1_2_8_31_1 article-title: The LSC17 leukemic stem cell signature predicts outcome in pediatric acute myeloid leukemia publication-title: Blood – ident: e_1_2_8_4_1 doi: 10.1038/bmt.2015.165 – ident: e_1_2_8_22_1 doi: 10.3324/haematol.2011.051714 – ident: e_1_2_8_32_1 doi: 10.1182/bloodadvances.2019001185 – volume: 15 start-page: 825 issue: 6 year: 1995 ident: e_1_2_8_19_1 article-title: 1994 Consensus conference on acute GVHD grading publication-title: Bone Marrow Transplant – ident: e_1_2_8_21_1 doi: 10.1002/ajh.24113 – ident: e_1_2_8_6_1 doi: 10.1182/blood-2009-11-254441 – ident: e_1_2_8_8_1 doi: 10.1182/blood-2016-08-733196
SSID	ssj0002315631
Score	2.2158637
Snippet	A 17‐gene stemness (LSC17) score determines risk in acute myeloid leukaemia patients treated with standard chemotherapy regimens. The present study further... A 17-gene stemness (LSC17) score determines risk in acute myeloid leukaemia patients treated with standard chemotherapy regimens. The present study further... Abstract A 17‐gene stemness (LSC17) score determines risk in acute myeloid leukaemia patients treated with standard chemotherapy regimens. The present study...
SourceID	doaj swepub pubmedcentral proquest pubmed crossref wiley
SourceType	Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	873
SubjectTerms	Acute leukaemia Acute myeloid leukemia Age AML Bone marrow Cell Therapy/Stem Cell Transplantation Chemotherapy Gene expression Leukemia LSC 17 score Management decisions Mortality Patients Remission (Medicine) Statistical analysis Stem cell transplantation Stem cells Transplantation Transplants & implants Variables
SummonAdditionalLinks	– databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdGJyFeEN8UBjISgqdoqe3YyQNCG9pUTVqFEJP2Fjn-2MJKUtZUiH-Hv5Q7x-kUMXhqFTuR4_v57mLf_Y6QtxowVEmLAQ6FSoSzMim85YmSGcus9spbzHc-Xcj5mTg5z853yGLIhcGwykEnBkVtW4N75PtMgXHjCvyLj6sfCVaNwtPVoYSGjqUV7IdAMXaH7DKsqjwhu4dHi89ftrsu4M1kks8GFtqU7X_DhFYRSBJv7FKg77_N5_w7dDISjI5922Ccjh-Q-9GrpAc9DB6SHdc8IndP47n5Y_Ib0EDBUABaHEXqZlRwdI0UllRHAbk1xU1Zitktq7WjGHROdWPpsm0uEtTgtN10MFnQ0QN62p9g9Sie2-NTa0MvNfK_tqu2xsRIikcCtAvc6UvdJzg1tG6oNpvO0e-_3LKt4eFucwX31foJOTs--vppnsTqDIkRiskED0C9FsZImAyubJr7DBy2tDCZmFmnfSGNyl3KQLWnRgoAQ47UMZWTaZV7zZ-SSdM27jmh0inpuSkypTVAxlaei2LmdZpZ0DFaTsn7QTalidTlWEFjWfaky6xEKZYgxSl5s-256uk6bulziOLdtiPBdrjQXl-Ucb2WXBYavrx8JYQBzGW5U-BNpArdaSvy2ZTsDeAo46pflzcYhXFsm2G94ozrxrWb0KdQHPODp-RZj6XtSLhEFZmpKVEjlI2GOm5p6svACV4IBq4cvNu7Ho-jW-KlK_jnSiSk4ww6Brz-c5bKk_kBg98X_3_Rl-Qew4SQEBK5Rybd9ca9Ajetq17HtfcH8B9Crg priority: 102 providerName: ProQuest – databaseName: Wiley Online Library Open Access dbid: 24P link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NbtQwELagSIgL4p-UgoyE4BQ1cfyTHAuiWlUq4kCl3iLHP23oNlk1iRC3PgJPwYPxJMw42aCIInHaVTyOvJ5vxrP2zGdC3mjAUCUtJjgUKubOyrjwNouVFExY7ZW3WO98_EmuTvjRqTidsiqxFmbkh5g33NAygr9GA9dVt_-HNPQrVqJyKW-TOyku-sjqzD_P-ysQtwgZriNkEsAAq5Dccs8mbH_bebEaBdL-myLNvxMmJ1rRZUQblqTDB-T-FEvSg1H5D8kt1zwid4-n0_LH5CdggKbq1_UPQImjSNmMjo12SF1J9aQY11HcjKVY1bLpHMVkc6obS9dtcwZ90XfTduhhfkDUA27ab7DeUTyxx_fWhp5rZH5tN22NJZEUDwNoH1jT13osbWpo3VBtht7Ry-9u3dbwejdcQL9aPyEnhx-_fFjF070MseGKyRiPPr3mxkiYkEzZJPcCQrWkMIKn1mlfSKNylzBw6omRHGCQI2lM5WRS5V5nT8lO0zbuOaHSKekzUwilNYDFVj7jRep1Iix4Fy0j8m6rn9JMpOV4d8a6HOmWWYmaLEGTEXk9S25Goo4bZN6jiud2pNYOD9qrs3Ky1DKThYb_XL7i3EA0K3KnII5IFAbSludpRPa2ACkne-9KpiD0yhTIwzjmZrBUnHHduHYIMoXKsDI4Is9GPM0jySQ6R6EiohZIWwx12dLU54ENvOAMgjj4bW9HTC66TI8u4JsrkYouYyAYMPvPWSqPVgcMPnf_V_AFucewKCSkRe6Rnf5qcC8hVOurV8EmfwNHikDi priority: 102 providerName: Wiley-Blackwell
Title	The 17‐gene stemness score associates with relapse risk and long‐term outcomes following allogeneic haematopoietic cell transplantation in acute myeloid leukaemia
URI	https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjha2.466 https://www.ncbi.nlm.nih.gov/pubmed/36051057 https://www.proquest.com/docview/2707537405 https://www.proquest.com/docview/2709734588 https://pubmed.ncbi.nlm.nih.gov/PMC9422016 http://kipublications.ki.se/Default.aspx?queryparsed=id:236051057 https://doaj.org/article/369a826fb44c40558e7eed079916d481
Volume	3
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2688-6146 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0002315631 issn: 2688-6146 databaseCode: DOA dateStart: 20200101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2688-6146 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0002315631 issn: 2688-6146 databaseCode: M~E dateStart: 20200101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 2688-6146 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0002315631 issn: 2688-6146 databaseCode: RPM dateStart: 20200101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVOVD databaseName: Journals@Ovid LWW All Open Access Journal Collection Rolling customDbUrl: eissn: 2688-6146 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0002315631 issn: 2688-6146 databaseCode: OVEED dateStart: 20200701 isFulltext: true titleUrlDefault: http://ovidsp.ovid.com/ providerName: Ovid – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 2688-6146 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0002315631 issn: 2688-6146 databaseCode: BENPR dateStart: 20210201 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVWIB databaseName: KBPluse Wiley Online Library: Open Access customDbUrl: eissn: 2688-6146 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0002315631 issn: 2688-6146 databaseCode: AVUZU dateStart: 20190101 isFulltext: true titleUrlDefault: https://www.kbplus.ac.uk/kbplus7/publicExport/pkg/559 providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library Open Access customDbUrl: eissn: 2688-6146 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0002315631 issn: 2688-6146 databaseCode: 24P dateStart: 20190101 isFulltext: true titleUrlDefault: https://authorservices.wiley.com/open-science/open-access/browse-journals.html providerName: Wiley-Blackwell
link	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELagSIgL4p9AWRkJwSlq1nbszbFFrVaVWlWISr1Zjn9o2m2yYhMhbjwCT8GD8STMONmlEUVcOCWKx5Ez83k8sT2fCXljAEOldLjBoVCp8E6mRXA8VTJnuTNBBYf5zkfHcn4qDs_ys2tHfeGesJ4euFfcDpeFgRA4lEJYCC7ymVfg1jOFcY0TMemawTB27WfqIpK4wH8Jn67ZZjO2c4GJqyKSIf4efyJN_02x5Z9bJAci0XEMGwehgwfk_hA90t2-1Q_JLV8_InePhvXxx-QHWJ1O1c9v3wEXniJJM7oyukKySmoGU_gVxelXinksy5WnuL2cmtrRRVN_grrorWnTtQBGEA2AlOYLjHAU1-jxvZWl5wa5XptlU2ESJMXpf9pGnvSF6ZOZalrV1Niu9fTqq180Fbzed5dQrzJPyOnB_sf383Q4iSG1QjGZ4mJnMMJaCQrhymWzkENwlhU2F1PnTSikVTOfMXDjmZUCDD9DmpjSy6ycBcOfkq26qf1zQqVXMnBb5MoYgIcrAxfFNJgsd-BPjEzIu7V9tB1oyvG0jIXuCZaZRktqsGRCXm8klz01xw0ye2jiTTmSaccHADE9QEz_C2IJ2V4DRA89fKWZgmCLK5CHdmyKoW-ixk3tmy7KFIpjLnBCnvV42rSES3SHuUqIGiFt1NRxSV2dR_7vQjAI2-Db3vaYHFUZHl3CnddIPscZCEbM_lVL-nC-y-D64n9o6yW5xzBFJG6S3CZb7efOv4LArS0n5DYTJxNyZ2__-OTDJPbYSZxf-wWuVUrP
linkProvider	Directory of Open Access Journals
linkToHtml	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKKwEXxJuFAkbicYqatR07OVSohVbbx1YItVJvwfGjDV2Spburqn-HH8JvYyZxtlpRuPW0q9iJ7MznmYk98w0hbzVgqJAWAxwyFQlnZZR5yyMlE5ZY7ZW3mO88PJCDI7F7nBwvkd9dLgyGVXY6sVHUtja4R77GFBg3rsC_-Dj-GWHVKDxd7Upo6FBawa43FGMhsWPPXV7AJ9xkfeczyPsdY9tbh58GUagyEBmhmIzwIM9rYYy0xnFl49Qn4HjEmUlE3zrtM2lU6mIGKio2UsCkUqRAKZyMi9RrDs-9RVbA7eCwqlY2tw6-fJ3v8oD3lEje71hvY7b2HRNoRUPKeGUHm3IB1_m4f4dqBkLTRV-6MYbb98m94MXSjRZ2D8iSqx6S28NwTv-I_AL0UTBMgE5HkSoaFSqdIGUm1QEQbkJxE5hiNs144igGuVNdWTqqq5MILQatZ1MQDnT0gNb6AqwsxTgBfGpp6KlGvtl6XJeYiEnxCIJOG672kW4TqipaVlSb2dTRH5duVJfwcDc7g_tK_Zgc3YicnpDlqq7cM0KlU9JzkyVKa4CoLTwXWd_rOLGg07TskQ-dbHITqNKxYscob0meWY5SzEGKPfJm3nPc0oNc02cTxTtvR0Lv5kJ9fpIH_ZBzmWn40vOFEAYwnqROgfcSK3TfrUj7PbLagSMPWmaSX60JGMe8GfQDvnFduXrW9MkUx3zkHnnaYmk-Ei5RJSeqR9QCyhaGuthSlacNB3kmGLiOMLf3LR4XbgmXzuCfy5EAjzPo2OD1n28p3x1sMPh9_v-JviZ3BofD_Xx_52DvBbnLMBmlCcdcJcvT85l7CS7itHgV1iEl32566f8BZM1_TQ
linkToPdf	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3dT9swELdYkdBepn2vg22etI-nqKnj2MkDmmBQFRgVmobEW-b4AzJK0tFWiH9nf87-qt0lTlE1tjeeWsVOZOd-vrvYd78j5J0CDOXCYIBDKgNujQhSZ6JAipjFRjnpDOY7H47E8Jjvn8QnK-R3mwuDYZWtTqwVtak07pH3mATjFknwL3rOh0Uc7Qw-TX4GWEEKT1rbchrKl1kwmzXdmE_yOLDXV_A5N93c2wHZv2dssPvt8zDwFQcCzSUTAR7qOcW1FkbbSJowcTE4IWGqY943VrlUaJnYkIG6CrXgMMEE6VByK8I8cSqC594jqxLzRTtkdXt3dPR1seMDnlQson7LgBuy3g9MpuU1QeONTaxLB9zm7_4dtunJTZf96towDh6SB96jpVsNBB-RFVs-JmuH_sz-CfkFSKRgpACpliJtNCpXOkX6TKo8OOyU4oYwxcyaydRSDHinqjR0XJWnAVoPWs1nICjo6AC51RVYXIoxA_jUQtMzhdyz1aQqMCmT4nEEndW87WPVJFeVtCip0vOZpRfXdlwV8HA7P4f7CvWUHN-JnJ6RTlmV9gWhwkrhIp3GUimAq8ldxNO-U2FsQL8p0SUfW9lk2tOmY_WOcdYQPrMMpZiBFLvk7aLnpKEKuaXPNop30Y7k3vWF6vI087oii0Sq4KvP5ZxrwHucWAmeTCjRlTc86XfJRguOzGucaXazPmAci2bQFfjGVWmred0nlRHmJnfJ8wZLi5FEAtVzLLtELqFsaajLLWVxVvORp5yBGwlz-9DgcekWf-kc_tkMyfAiBh1rvP7zLWX7wy0Gvy__P9E3ZA1UQPZlb3SwTu4zzEupIzM3SGd2ObevwFuc5a_9MqTk-12v_D8iRIOH
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+17%E2%80%90gene+stemness+score+associates+with+relapse+risk+and+long%E2%80%90term+outcomes+following+allogeneic+haematopoietic+cell+transplantation+in+acute+myeloid+leukaemia&rft.jtitle=EJHaem&rft.au=Dennis+D.+H.+Kim&rft.au=Igor+Novitzky+Basso&rft.au=Taehyung+Simon+Kim&rft.au=Seong+Yoon+Yi&rft.date=2022-08-01&rft.pub=Wiley&rft.eissn=2688-6146&rft.volume=3&rft.issue=3&rft.spage=873&rft.epage=884&rft_id=info:doi/10.1002%2Fjha2.466&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_369a826fb44c40558e7eed079916d481
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2688-6146&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2688-6146&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2688-6146&client=summon